GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy ...Middle East

HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND)...

Hence then, the article about geneditbio receives fda clearance of ind application for its lead in vivo genome editing program geb 101 for tgfbi corneal dystrophy was published today ( Monday 05/01/2026 - 07:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy )

Also on site :

• Who Is Scarab on ‘The Masked Singer’? You Can’t Beet-le These Guesses!
• Missing Central Coast woman found in East Bay after escaping alleged abuser
• Who Is Googly Eyes on The Masked Singer? Monster Hits Lead to Great Guesses!